GcMAF and/or oral MAF immunotherapy are recommended for the management of conditions characterized by immune dysfunction or compromised immune systems, including but not limited to:
| Cancer |
Autoimmune diseases |
Respiratory tract infections |
| Autism Spectrum Disorders (ASD) |
Herpes Simplex virus (HSV) |
Epstein-Barr Virus (EBV) |
| Chronic Fatigue Syndrome (CFS) |
Multiple sclerosis (MS) |
Cystitis |
| Myalgic Encephalomyelitis (ME) |
Rheumatoid arthritis (RA) |
Urinary tract infection (UTI) |
| Tuberculosis |
Lyme disease (Lyme borreliosis) |
Endometriosis |
| Lupus (Systemic lupus erythematosus, SLE) |
Mycobacteria infections |
Parkinson's disease |
| Pneumonia infection |
Fibromyalgia |
Norovirus |
| Malaria |
Warts caused by viral infection |
Herpes simplex virus (HSV) |
| Q fever (Coxiella burnetii) |
Influenza virus (flu) |
Chicken pox (varicella zoster virus) |
| Psoriasis |
Polycystic ovary syndrome (PCOS) |
Ulcerative colitis, Crohn's disease |
